Allergy Therapeutics PLC Director/PDMR Shareholding (6074I)
15 December 2020 - 2:58AM
UK Regulatory
TIDMAGY
RNS Number : 6074I
Allergy Therapeutics PLC
14 December 2020
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Director/PDMR Shareholding
The Company was notified on 8 December 2020 that Wild Indigo SA
("Wild Indigo"), a company of which Manuel Llobet, Chief Executive
Officer, has indirect interests, transferred 3,125,000 ordinary
shares of 0.1 pence each in the capital of the Company ("Ordinary
Shares") to Mr Llobet for estate planning purposes. The transfer of
Ordinary Shares represents approximately 94 per cent. of Mr
Llobet's entire holding in the Company.
Mr Llobet is a Director and PDMR and Wild Indigo is deemed to be
a person closely associated with Mr Llobet under Article 19 of the
EU Market Abuse Regulation 596/2014.
Following the transfer of shares, Mr Llobet 's holding of
Ordinary Shares remains unchanged at a total of 3,325,000 Ordinary
Shares, representing 0.52 % of the issued share capital of the
Company.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and/or persons closely
associated with them:
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Manuel Llobet
------------------------------------------------------------ ----------------------------------------
2 Reason for the notification
------------------------------------------------------------------------------------------------------
Chief Executive Officer , Director
a) Position/status
------------------------------------------------------------ ----------------------------------------
b) Initial notification/Amendment Initial Notification
------------------------------------------------------------ ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------------------------
a) Name Allergy Therapeutics plc
------------------------------------------------------------ ----------------------------------------
b) LEI 213800PQ7AHK7KGVOE23
------------------------------------------------------------ ----------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of instrument 0.1p ordinary shares
Identification code
GB00B02LCQ05
------------------------------------------------------------ ----------------------------------------
b) Nature of the transaction Transfer of shares from Wild Indigo to
Manuel Llobet (direct interests)
------------------------------------------------------------ ----------------------------------------
c) Price(s) and volume(s) Price(s) per Ordinary Volume(s)
Share
N/A - transfer
of beneficial interests 3,125,000
------------------------------------------------------------ ----------------------------------------
d) Aggregated information
N/A
N/A
------------------------------------------------------------ ----------------------------------------
e) Date of the transaction 8 December 2020
------------------------------------------------------------ ----------------------------------------
f) Place of the transaction London Stock Exchange - AIM
------------------------------------------------------------ ----------------------------------------
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott, David Daley, Ashley Tapp, Olivia Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company focussed on the treatment and diagnosis of
allergic disorders, including aluminium free immunotherapy vaccines
that have the potential to cure disease. The Group sells
proprietary and third party products from its subsidiaries in nine
major European countries and via distribution agreements in an
additional ten countries. Its broad pipeline of products in
clinical development include vaccines for grass, tree and house
dust mite, and peanut allergy vaccine in pre-clinical development.
Adjuvant systems to boost performance of vaccines outside allergy
are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m(2) of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved over 9% compound annual
growth since formation, employs c.600 employees and is listed on
the London Stock Exchange (AIM:AGY). For more information, please
see www.allergytherapeutics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBUBDDGUBDGGS
(END) Dow Jones Newswires
December 14, 2020 10:58 ET (15:58 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2024 to May 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From May 2023 to May 2024